Cyclo(Arg-Gly-Asp-D-Phe-Val) peptide

Cyclo(Arg-Gly-Asp-D-Phe-Val) peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

c(RGDfV)

Cyclo(Arg-Gly-Asp-D-Phe-Val)

5

95%

C₂₆H₃₈N₈O₇

574.64

Synthetic

Powder

c(RGDfV) is a potent inhibitor of cell adhesion. It inhibited tumor cell adhesion to laminin and vitronectin substrates. In vivo investigations in rats provided the first evidence of its utility in the amelioration of ischemic acute renal failure. c(RGDfV) inhibited tubular obstruction by preventing cell-cell adhesion. Hammes et al. showed that the cyclopeptide can also be used to prevent retinal neovascularization. c(RGDfV) binds to αvβ3 receptors.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• M. Friedlander, C.L. Theesfeld, M. Sugita, M. Fruttiger, M.A. Thomas, S. Chang, and D.A. Cheresh, Proc. Natl. Acad. Sci. USA, 93, 9764 (1996). (Pharmacol.)

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.